How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

129 results for

5-Aminosalicylic Acid Derivative

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. (Abstract)

Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Crohn's disease (CD) is a chronic inflammatory disorder that can involve any part of the gastrointestinal tract. 5-Aminosalicylates (5-ASAs) are locally acting, anti-inflammatory compounds that reduce inflammation of the colonic mucosa with release profiles that vary among various commercially available formulations. This updated Cochrane review summarizes current evidence on the use of 5-ASA (...) experienced an adverse event during a follow-up of 3 to 72 months (RR 1.07, 95% CI 0.60 to 1.91; I² = 0%; low certainty evidence). Adverse event rates were similar in the 5-ASA and purine analogues groups. However, serious adverse events and withdrawals due to adverse events were more common in participants who received purine analogues than 5-ASA. At 52 weeks to 24 months, 52% (107/207) of 5-ASA participants had an adverse event compared to 47% (102/218) of purine analogue participants (RR 1.11, 95% CI

2019 Cochrane Controlled trial quality: predicted high

2. 5-Aminosalicylic Acid Derivative

5-Aminosalicylic Acid Derivative 5-Aminosalicylic Acid Derivative Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 5-Aminosalicylic (...) Acid Derivative 5-Aminosalicylic Acid Derivative Aka: 5-Aminosalicylic Acid Derivative , 5-ASA From Related Chapters II. Indications III. Preparations Sulfa containing agents ( ) Sulfa-free agents ( , , ) Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "5-Aminosalicylic Acid Derivative." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics

2018 FP Notebook

3. Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity Full Text available with Trip Pro

Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity 5-[(4-carboxybutanoyl)amino]-2-hydroxybenzoic acid (C2) is a novel synthetic derivative of 5-aminosalicylic acid (5-ASA), which is currently being evaluated ex vivo as an anti-inflammatory agent and has shown satisfactory results. This study aimed to obtain the pharmacokinetic profiles, tissue distribution

2016 PloS one

4. Safety of 5-Aminosalicylic Acid Derivatives in Patients with Sensitivity to Acetylsalicylic Acid and Nonsteroidal Anti-inflammatory Drugs Full Text available with Trip Pro

Safety of 5-Aminosalicylic Acid Derivatives in Patients with Sensitivity to Acetylsalicylic Acid and Nonsteroidal Anti-inflammatory Drugs One of the cornerstones of the management of inflammatory bowel disease is the use of 5-aminosalicylic acid (5-ASA) compounds for treatment of flares and as maintenance therapy during remission. There are concerns about using 5-ASA in patients with a history of hypersensitivity to acetylsalicylic acid (ASA).To assess the literature with respect to the safety (...) of 5-ASA compounds in patients with documented sensitivity to ASA or nonsteroidal anti-inflammatory drugs (NSAIDs).A literature search was conducted in the MEDLINE and Embase databases, using various search terms, including "aminosalicylic acids", "non-steroidal anti-inflammatory agents," "hypersensitivity", and "allergy". The search was limited to articles (of any study design) published in English. Abstracts, full articles, and reference lists from retrieved articles were assessed to identify

2014 The Canadian journal of hospital pharmacy

5. 5-Aminosalicylic Acid Derivative

5-Aminosalicylic Acid Derivative 5-Aminosalicylic Acid Derivative Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 5-Aminosalicylic (...) Acid Derivative 5-Aminosalicylic Acid Derivative Aka: 5-Aminosalicylic Acid Derivative , 5-ASA From Related Chapters II. Indications III. Preparations Sulfa containing agents ( ) Sulfa-free agents ( , , ) Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "5-Aminosalicylic Acid Derivative." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics

2015 FP Notebook

6. 5-Aminosalicylic acid attenuates allergen-induced airway inflammation and oxidative stress in asthma. (Abstract)

in the development of status asthmaticus. Anti-inflammatory corticosteroids are being widely used for treating allergic asthma. In the present study 5-aminosalicylic acid (5-ASA), a salicylic acid derivative, was evaluated, in vivo for its potential to suppress TNF-α, IL-6 and IL-13 using ovalbumin (OVA) induced allergic asthma in Balb/C mice. Oral administration of 65, 130 and 195 mg/kg 5-ASA significantly reduced the OVA induced total and differential leucocyte count, TNF-α, IL-6, IL-13, nitrite, nitrate, MDA (...) 5-Aminosalicylic acid attenuates allergen-induced airway inflammation and oxidative stress in asthma. Pro-inflammatory cytokines regulate the magnitude of allergic reactions during asthma. Tumor necrosis factor--alpha (TNF-α), interleukin-6 (IL-6) and interleukin-13 (IL-13) play a crucial role in aggravating the inflammatory conditions during allergic asthma. In addition, oxidative stress contributes to the pathogenesis of asthma by altering the physiological condition resulting

2014 Pulmonary Pharmacology & Therapeutics

7. 5-aminosalicylic Acid and chemoprevention: does it work? (Abstract)

5-aminosalicylic Acid and chemoprevention: does it work? 5-Aminosalicylic acid (5-ASA)-containing drugs are the mainstay of therapy in inflammatory bowel disease (IBD). Intestinal inflammation is the main risk factor for colorectal cancer (CRC) in IBD. Hence, all drugs that are able to induce and maintain mucosal healing (MH) may prevent CRC risk in IBD. In patients with mild to moderate ulcerative colitis (UC), a recent systematic review of 5-ASA trials demonstrated that MH was achieved (...) in nearly 50% of patients. A systematic review including 48 studies linked 5-ASA chemopreventive properties to five distinct pathways: cell cycle progression, scavenging of reactive oxygen- or nitrogen-derived metabolites, TNF-α/TGF-ss signaling, WNT/β-catenin signaling and antibacterial properties. Therefore, in addition to their overall anti-inflammatory activity on the intestinal mucosa, 5-ASA compounds have specific effects on colorectal carcinogenesis at the molecular level. In 2005, a landmark

2013 Digestive diseases (Basel, Switzerland)

8. Nephrotoxic Lesions from 5-Aminosalicylic Acid Full Text available with Trip Pro

Nephrotoxic Lesions from 5-Aminosalicylic Acid 5-Aminosalicylic acid given to rats as a single intravenous injection led to necrosis of the proximal convoluted tubules and of the renal papilla. These two lesions developed at the same time and the cortical lesions did not appear to be a consequence of the renal papillary necrosis. Since the compound possesses the molecular structure both of a phenacetin derivative and of a salicylate these observations may be relevant to the problem of renal

1972 British medical journal

9. Sulfa-free 5-Aminosalacylic acid

, 363629007 , 86977007 English Mesalamine , Mesalazine duplicate deleted , 5 Aminosalicylic Acid , 5-Aminosalicylic Acid , 5-Amino-2-hydroxybenzoic Acid , m Aminosalicylic Acid , m-Aminosalicylic Acid , meta Aminosalicylic Acid , meta-Aminosalicylic Acid , mesalamine (medication) , mesalamine (Rowasa) , MESALAMINE , Mesalamine [Chemical/Ingredient] , 5 asa , m-aminosalicylic acid , 5-asa , asa 5 , mesalazine , Mesalazine duplicate deleted (product) , Mesalamine product (product) , 5-aminosalicylic acid (...) (substance) , 5-ASA , 5-Aminosalicylic acid , Fisalamine , m-Aminosalicylic acid , Mesalamine (substance) , 5-aminosalicylic acid , 5ASA - Mesalazine , Mesalamine (product) , Mesalamine product , Mesalamine product (substance) , Mesalazine duplicate deleted (substance) , Mesalazine , mesalamine Swedish Mesalamin Czech mesalazin , mesalamin Finnish Mesalatsiini Russian MEZALAMIN , MEZALAZIN , 5-AMINOSALITSILAT , 5-АМИНОСАЛИЦИЛАТ , МЕЗАЛАЗИН , МЕЗАЛАМИН Spanish mesalazina , mesalamina , mesalazina

2018 FP Notebook

10. Purine analogues compared with mesalamine or 5-ASA for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis (Abstract)

Purine analogues compared with mesalamine or 5-ASA for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis Objective:  To use a meta-analysis approach to evaluate the efficacy and safety of purine analogues, azathioprine (AZA) and 6-mercaptopurine (6-MP), in the prevention of postoperative recurrence of Crohn's disease (CD), as compared with mesalamine or 5-aminosalicylic acid (5-ASA). Methods:  The Pubmed, Cochrane Library, and Embase literature databases were (...) searched for relevant studies with the key words "azathioprine", "6-mercaptopurine", "purine analogue", "mesalamine", or "5-ASA". The efficacy and safety of purine analogues in the retrieved randomized controlled trials (RCTs) were evaluated with RevMan 5.0.25 (The Cochrane Collaboration, Oxford, England) and STATA 12.0 (Stata Corporation, College Station, TX, USA). The outcome measures of AZA and 6-MP, compared to mesalamine and 5-ASA (control arms), were: clinical recurrence, endoscopic recurrence

2012 EvidenceUpdates

11. Do patients taking sulfasalazine for rheumatological or gastroenterological indications need to take 5mg folic acid rather than 400mcg pre-conception and in early (or even later) pregnancy?

two active parts, sulfapyridine and 5-aminosalicylic acid. Sulfasalazine can actively inhibit the absorption and metabolism of folic acid. Since the drug is so poorly absorbed from the GI tract, a large effect of this action will be exerted on dietary folic acid. This may therefore result in folic acid deficiency. For that reason, it is advised that pregnant patients undergoing treatment with sulfasalazine take high dose supplementary folic acid to reduce the risk of congenital defects (...) Do patients taking sulfasalazine for rheumatological or gastroenterological indications need to take 5mg folic acid rather than 400mcg pre-conception and in early (or even later) pregnancy? Do patients taking sulfasalazine for rheumatological or gastroenterological indications need to take 5mg folic acid rather than 400mcg pre-conception and in early (or even later) pregnancy? - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere

2012 TRIP Answers

12. Sulfa-free 5-Aminosalacylic acid

, 363629007 , 86977007 English Mesalamine , Mesalazine duplicate deleted , 5 Aminosalicylic Acid , 5-Aminosalicylic Acid , 5-Amino-2-hydroxybenzoic Acid , m Aminosalicylic Acid , m-Aminosalicylic Acid , meta Aminosalicylic Acid , meta-Aminosalicylic Acid , mesalamine (medication) , mesalamine (Rowasa) , MESALAMINE , Mesalamine [Chemical/Ingredient] , 5 asa , m-aminosalicylic acid , 5-asa , asa 5 , mesalazine , Mesalazine duplicate deleted (product) , Mesalamine product (product) , 5-aminosalicylic acid (...) (substance) , 5-ASA , 5-Aminosalicylic acid , Fisalamine , m-Aminosalicylic acid , Mesalamine (substance) , 5-aminosalicylic acid , 5ASA - Mesalazine , Mesalamine (product) , Mesalamine product , Mesalamine product (substance) , Mesalazine duplicate deleted (substance) , Mesalazine , mesalamine Swedish Mesalamin Czech mesalazin , mesalamin Finnish Mesalatsiini Russian MEZALAMIN , MEZALAZIN , 5-AMINOSALITSILAT , 5-АМИНОСАЛИЦИЛАТ , МЕЗАЛАЗИН , МЕЗАЛАМИН Spanish mesalazina , mesalamina , mesalazina

2015 FP Notebook

13. Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis. Full Text available with Trip Pro

included 35 RCTs (3249 participants) in the review. The average age of study participants ranged between 33.6 and 38.8 years. Risk of bias was high in 18 studies, low in four studies, and unclear in 13 studies. Of the 35 included RCTs, 26 studies (2581 participants; 9 interventions) were considered eligible for inclusion in the NMA. The interventions studied included 5-aminosalicylic acid (5-ASA), adalimumab, antibiotics, budesonide, infliximab, probiotics, purine analogues, sulfasalazine (...) networks. We mainly judged individual contrasts as of low or very low certainty, except 5-ASA versus placebo, the evidence for which was judged as of moderate certainty.We ranked the treatments based on effectiveness and the certainty of the evidence. For clinical relapse, the five most highly ranked treatments were adalimumab, infliximab, budesonide, 5-ASA, and purine analogues. We found some evidence that adalimumab (HR 0.11, 95% Crl 0.02 to 0.33; low-certainty evidence) and 5-ASA may reduce

2019 Cochrane

14. Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contrai

of special interest ASA Acetylsalicylic acid ATC Anatomical Therapeutic Chemical [classification system] ATMP Advanced therapy medicinal product BF Biologic failure BID Twice daily CD Crohn’s disease CI Confidence interval CrI Credible interval CRP C-reactive protein CSR Clinical study report CTR Clinical trial register DIC Deviance information criterion ECCO European Crohn's and Colitis Organisation EL Evidence level EMA European Medicines Agency EOW Every other week EQ-5D EuroQol Questionnaire 5 (...) Dimensions EQ-VAS EuroQol Visual Analogue Scale GOL Golimumab GRADE Grading of Recommendations, Assessment, Development and Evaluation HRQoL Health-related quality of life HTAi Health Technology Assessment International IBDQ Inflammatory Bowel Disease Questionnaire IFX Infliximab IL Interleukin IPD Individual patient data ITT Intention to treat IV Intravenous MAH Marketing authorisation holder MCS Mental component summary MD Mean difference MeSH Medical Subject Headings MTX Methotrexate NA Not applicable

2020 EUnetHTA

15. BSG expanded consensus advice for the management of Inflammatory Bowel Disease during the COVID-19 pandemic Full Text available with Trip Pro

Kinase inhibitors (tofacitinib) No evidence of increased risk of COVID-19 infection 5-Aminosalicylate acid derivatives (mesalazine etc.) No evidence of increased risk of COVID-19 infection In UC patients with uncontrolled symptoms, oral 5ASA dose should be optimised +/- addition of topical (rectal) 5ASA 5) Service considerations The infusion service is a priority area. Consider moving off-site to a ‘clean’ area possible. Visitors should no longer be permitted. Patients should not attend for infusion (...) regardless of co-morbidity and who meet one or more of the following criteria: Biologic plus immunomodulator** in stable patients Rectal therapies Intravenous or oral steroids ≥20 mg prednisolone or equivalent per day (only while on this dose) Ustekinumab Orally administered topically acting steroids (budesonide or beclometasone) Commencement of biologic plus either immunomodulator or systemic steroids within previous 6 weeks** Vedolizumab Therapies for bile acid diarrhoea (colestyramine, colesevelam

2020 British Society of Gastroenterology

16. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn’s Disease

. Vote: strongly agree, 67%; agree, 33%. Recommendation 2: In patients with moderate CD limited to the colon, we suggest against the use of sulfasalazine to induce clinical remission. GRADE: Conditional recommendation, very-low-quality evidence. Vote: strongly agree, 67%; agree, 20%; neutral, 7%; disagree, 0%; strongly disagree, 7%. Recommendation 3: In patients with CD in clinical remission, we recommend against sulfasalazine or 5-aminosalicylic acid to maintain clinical remission. GRADE: Strong (...) 3: In patients with Crohn’ s disease in clin- ical remission, we recommend against sulfasalazine or 5-aminosalicylic acid to maintain clinical remission. GRADE: Strong recommendation, very-low-quality evidence. Vote: strongly agree, 33%; agree, 47%; neutral, 20%. No consensus C: In patients with mild Crohn’s disease who have achieved clinical remission with sulfasalazine or 5-aminosalicylic acid, the consensus group does not make a recommendation (for or against) regarding contin- uing

2019 Canadian Association of Gastroenterology

17. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease

and Searches The Editorial Office of the Cochrane Upper Gastrointestinal and Pancreatic Diseases Group at McMaster University performed a systematic literature search of MEDLINE (1946 on), EMBASE (1980 on), and CENTRAL (Cochrane Central Register of Controlled Trials) for trials published through February–April 2016. Key search terms included Crohn, anti- biotic, 5-aminosalicylate, corticosteroid, anti-tumor necrosis factor, thiopurine, methotrexate, vedolizumab, ustekinumab, probiotics, omega-3 fatty acid (...) , Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then finalized and voted on by a group of specialists. Results: The consensus includes 41 statements focused on 6 main drug classes: antibiotics, 5-aminosalicylate, corticosteroids, immunosuppressants, biologic therapies, and other therapies. The group suggested against the use of antibiotics or 5-aminosalicylate as induction or maintenance ther- apies. Corticosteroid therapies (including

2019 Canadian Association of Gastroenterology

18. A cost-utility analysis of biosimilar infliximab compared to reference infliximab in adult switch patients with Crohn’s disease: A Canadian analysis

- Proportion in Remission & Response States 100 Figure 9 - Societal Perspective Results (1,000 of 10,000 iterations with 95% Confidence Ellipse) 101 Figure 10 Cost Effectiveness Acceptability Curve 110 12 List of Appendices Appendix I – Biosimilar Observational Studies 168 Appendix II – Drug Price Distributions 171 Appendix III – Physician Fee Distributions 172 13 List of Abbreviations 5-ASA – 5-Aminosalicylates 6-MP – 6-mercaptopurine ADA – Anti-Drug Antibodies BIA – Budget Impact Analysis CADTH (...) primary categories of pharmaceuticals that are used to treat CD in Canada which are summarized in Table 5. 29 Table 5 - Treatment Categories Category Drugs Used to Treat Effectiveness Antibiotics Metronidazole, ciprofloxacin Fistula treatment Bacterial infections or abscesses Effective in treating the complications of CD Controlled trials have not consistently demonstrated efficacy in the treatment of the primary processes 5-Aminosalicylates (5- ASA) Sulfasalazine, mesalamine Mild to moderate CD Acute

2019 SickKids Reports

19. The economic evaluation of early intervention with Anti-Tumor Necrosis Factor-alpha treatments in pediatric Crohn's disease

-Ellen Hogan, Mr. Austin Nam, Dr. Petros Pechlivanoglou, Dr. Peter Austin, Dr. Jan Barnsley and Dr. Eleanor Pullenayegum for their help and suggestions in tackling this project. Thanks also to Dr. David Naimark, Dr. Lusine Abrahamyan, Dr. Beate Sander, Dr. Walter Wodchis, Dr. Wanrudee Isaranuwatchai, Dr. Murray Krahn, Dr. Myla Moretti, and Ms. Kate Tsiplova for their insight. List of Abbreviations 5-ASA 5-aminosalicylic acid 6-MP 6-mercaptopurine ADA Adalimumab AZA Azathioprine CAD Canadian dollar (...) Appendix 12. The Weighted Average Cost of Corticosteroids Per Week and Per Weight. 243 Appendix 13. The Weighted Average Cost of Antibiotics Per Week and Per Weight. 245 Appendix 14. The Weighted Average Cost of Oral 5-Aminosalicylates Per Week and Per Weight. 246 Appendix 15. The Mean Cost Per Week for Enteral Nutrition Supplements. 247 Appendix 16. Distribution of Imputed of Albumin. 249 Appendix 17. Propensity Score Differences in Unadjusted CD RISK-PROKIIDS Patient Population. 251 Appendix 18

2019 SickKids Reports

20. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis Full Text available with Trip Pro

., and Ilstrup, D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med . 1987 ; 317 : 1625–1629 | | Although disease activity exists on a spectrum, patients in the mild–moderate category who have more frequent bowel movements, more prominent rectal bleeding, or greater overall inflammatory burden should be considered to have moderate disease. Patients with mild–moderate disease activity generally are at low risk of requiring (...) of this guideline and the technical review, low-dose mesalamine was defined as a total daily dose <2 g, standard dose as 2–3 g/d, and high dose as >3 g/d. High-dose, x 4 Schroeder, K.W., Tremaine, W.J., and Ilstrup, D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med . 1987 ; 317 : 1625–1629 | | , x 11 Ito, H., Iida, M., Matsumoto, T. et al. Direct comparison of two different mesalamine formulations for the maintenance of remission

2019 American Gastroenterological Association Institute

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>